Showing results 1 to 1 of 1
Issue Date | Title | Journal Title |
---|---|---|
2022 | First-in-human phase 1 study of the anti-TIGIT antibody vibostolimab as monotherapy or with pembrolizumab for advanced solid tumors, including non-small-cell lung cancer | ANNALS OF ONCOLOGY |